WuXi Biologics (Cayman) Inc.

SEHK:2269 Stock Report

Market Cap: HK$67.5b

WuXi Biologics (Cayman) Valuation

Is 2269 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2269 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2269 (HK$17.34) is trading below our estimate of fair value (HK$39.54)

Significantly Below Fair Value: 2269 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2269?

Key metric: As 2269 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2269. This is calculated by dividing 2269's market cap by their current earnings.
What is 2269's PE Ratio?
PE Ratio25.2x
EarningsCN¥2.63b
Market CapCN¥62.93b

Price to Earnings Ratio vs Peers

How does 2269's PE Ratio compare to its peers?

The above table shows the PE ratio for 2269 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.9x
2268 WuXi XDC Cayman
54x27.1%HK$33.0b
1521 Frontage Holdings
57.1x64.8%HK$2.7b
1093 CSPC Pharmaceutical Group
10.5x2.7%HK$57.1b
1177 Sino Biopharmaceutical
26x12.9%HK$59.0b
2269 WuXi Biologics (Cayman)
25.2x17.4%HK$67.5b

Price-To-Earnings vs Peers: 2269 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (36.9x).


Price to Earnings Ratio vs Industry

How does 2269's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
2269 25.2xIndustry Avg. 31.3xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2269 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the Asian Life Sciences industry average (31.3x).


Price to Earnings Ratio vs Fair Ratio

What is 2269's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2269 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.2x
Fair PE Ratio15.8x

Price-To-Earnings vs Fair Ratio: 2269 is expensive based on its Price-To-Earnings Ratio (25.2x) compared to the estimated Fair Price-To-Earnings Ratio (15.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2269 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$17.34
HK$18.83
+8.6%
38.8%HK$34.37HK$9.81n/a25
Nov ’25HK$16.32
HK$19.44
+19.1%
39.8%HK$34.98HK$9.98n/a26
Oct ’25HK$17.50
HK$19.57
+11.8%
43.8%HK$42.50HK$10.14n/a26
Sep ’25HK$11.22
HK$19.28
+71.9%
44.8%HK$42.15HK$8.53n/a26
Aug ’25HK$11.42
HK$21.34
+86.8%
38.5%HK$42.03HK$8.50n/a25
Jul ’25HK$11.54
HK$22.64
+96.1%
44.9%HK$53.20HK$11.91n/a25
Jun ’25HK$11.14
HK$26.44
+137.3%
58.2%HK$73.15HK$11.95n/a26
May ’25HK$13.74
HK$28.52
+107.6%
55.3%HK$73.29HK$11.97n/a26
Apr ’25HK$14.30
HK$34.62
+142.1%
53.2%HK$73.42HK$11.99n/a28
Mar ’25HK$18.80
HK$51.40
+173.4%
33.9%HK$117.35HK$21.89n/a29
Feb ’25HK$21.15
HK$51.52
+143.6%
33.9%HK$117.31HK$21.89n/a29
Jan ’25HK$29.60
HK$53.09
+79.4%
34.6%HK$117.88HK$21.99n/a29
Dec ’24HK$43.50
HK$75.73
+74.1%
19.9%HK$117.39HK$47.59HK$15.0027
Nov ’24HK$47.90
HK$74.23
+55.0%
19.6%HK$112.74HK$46.69HK$16.3227
Oct ’24HK$45.65
HK$77.39
+69.5%
23.8%HK$135.64HK$46.85HK$17.5029
Sep ’24HK$44.15
HK$79.25
+79.5%
23.2%HK$136.69HK$47.21HK$11.2229
Aug ’24HK$44.60
HK$81.04
+81.7%
24.6%HK$137.31HK$29.87HK$11.4229
Jul ’24HK$37.55
HK$81.72
+117.6%
23.5%HK$136.58HK$29.71HK$11.5429
Jun ’24HK$41.75
HK$87.21
+108.9%
17.5%HK$139.52HK$67.09HK$11.1429
May ’24HK$46.45
HK$89.34
+92.3%
17.5%HK$143.60HK$69.05HK$13.7429
Apr ’24HK$48.60
HK$89.91
+85.0%
17.5%HK$144.55HK$69.52HK$14.3029
Mar ’24HK$58.30
HK$101.07
+73.4%
24.7%HK$198.38HK$69.50HK$18.8028
Feb ’24HK$67.05
HK$104.22
+55.4%
24.5%HK$200.39HK$70.20HK$21.1528
Jan ’24HK$59.85
HK$100.50
+67.9%
27.7%HK$203.95HK$45.66HK$29.6029
Dec ’23HK$50.65
HK$99.01
+95.5%
27.7%HK$200.82HK$44.96HK$43.5029

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies